Research programme: cancer and influenza virus vaccines - ImmunityBio
Alternative Names: Breast cancer vaccine - ImmunityBio; Head and neck cancer vaccine - ImmunityBio; HER vaccine - ImmunityBio; HPV-H&N cancer vaccine - ImmunityBio; WT-1-targeted vaccine - ImmunityBioLatest Information Update: 28 Jun 2021
At a glance
- Originator Etubics Corporation
- Developer ImmunityBio
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Head and neck cancer; Malignant melanoma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 08 Jan 2018 NantKwest plans the phase Ib/II QUILT-3.067 trial for Triple negative breast cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (NCT03387085)
- 27 Dec 2017 National Cancer Institute plans a phase I trial for Prostate, Lung, Breast and Colon cancer (Late-stage disease) in USA , (NCT03384316)